Ascentage Pharma Group International (AAPG) Income from Non-Controlling Interests (2023 - 2024)
Ascentage Pharma Group International posted quarterly Income from Non-Controlling Interests of $1.4 million for Q4 2024, down 2.19% year-on-year from $1.4 million in Q1 2024, and down 2.19% on a QoQ basis from $1.4 million in Q4 2023.
Ascentage Pharma Group International (AAPG) has 2 years of Income from Non-Controlling Interests data on file, last reported at $1.4 million in Q4 2024.
- For the quarter ending Q4 2024, Income from Non-Controlling Interests fell 2.19% year-over-year to $1.4 million; the trailing twelve-month figure through Dec 2024 stood at $1.4 million (down 2.19% YoY), and the FY2025 full-year result was -$31000.0, down 102.27% from the prior year.
- Income from Non-Controlling Interests for Q4 2024 stood at $1.4 million, down from $1.4 million in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $1.4 million in Q4 2023 and bottomed at $1.4 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | -13.75 Mn |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | - |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | - |
| 10 | Ascentage Pharma Group International | 1.11 Bn | 937.28 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1.39 Mn |
| Dec 31, 2023 | 1.42 Mn |